EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TRIM56 enhances adenoviral E1A steady state to improve oncolytic adenovirus therapy efficacy

Nan Sun iD, Jikai Zhang, Chen Zhang, Hang Yin, Botao Zou, Yunfeng Geng, Wanjun Gao, Yuxin Zhang, Gang Wang iD, Junnian Zheng iD, Lin Fang iD

Journal of Virology · 2025

DOI: 10.1128/jvi.00041-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Nan Sun und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Oncolytic Viruses, Adenovirus E1A Proteins, Tripartite Motif Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncolytic adenoviruses (OAVs) engineered to carry antitumor or immune-activating transgenes are being actively explored for cancer immunotherapy. While many efforts have focused on modifying OAVs to counteract the immunosuppressive tumor microenvironment, comparatively less attention has been given to enhancing OAV replication by targeting host factors to increase oncolytic activity. Here, we report that TRIM56 is strongly upregulated during HAdV-C5 infection, with its expression correlating with increasing levels of the viral E1A protein, ultimately promoting HAdV-C5 replication. Mechanistically, TRIM56 stabilizes the viral E1A protein and enhances viral genome transcription. To leverage this effect, we engineered a recombinant oncolytic adenovirus expressing TRIM56 (OAV-TRIM56) and found that it achieved significantly higher replication titers in vitro compared to conventional OAVs, leading to superior antitumor efficacy in vivo . Our study presents a novel strategy to enhance OAV replication by targeting host factors, offering a promising approach for improving oncolytic virotherapy. IMPORTANCE Adenoviruses (Ads) can be engineered into replication-defective adenoviral (Adv) vectors and replication-competent oncolytic adenovirus (OAd), both of which are widely used in gene therapy and virotherapy. Understanding the mechanisms regulating adenoviral infection is crucial for optimizing the therapeutic potential of Adv and OAd. In this study, we demonstrate for the first time that TRIM56, a host protein broadly expressed in various cell types, stabilizes the adenoviral E1A protein and assists E1A in antagonizing STING, thereby significantly enhancing adenoviral replication. Our findings provide new insights into strategies for improving the efficacy of Adv and OAd in gene therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncolytic VirotherapyOncolytic VirusesAdenovirus E1A ProteinsTripartite Motif ProteinsUbiquitin-Protein LigasesAdenoviridaeHumansVirus ReplicationAnimalsMiceCell Line, TumorNeoplasmsGenetic Therapy

Stichwörter der Autor:innen

E1ASTINGTRIM56adenovirusesoncolytic viruses

Substanzen

Adenovirus E1A ProteinsTripartite Motif ProteinsUbiquitin-Protein Ligases

Autor:innen und Institutionen

  • Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.
  • Center of Clinical Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
  • Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.
  • Department of Pathogen Biology and Immunology, Biology and Immunology, Jiangsu Key Laboratory of Immunity and Metabolism, School of Basic Medical Sciences, Xuzhou Medical University, Xuzhou, Jiangsu, China.
  • Department of Oncology, The First People's Hospital of Yancheng, Yancheng, Jiangsu, China.

ORCID-Profile: Nan Sun, Gang Wang, Junnian Zheng, Lin Fang

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province

Zitieren

APA

Sun, N., Zhang, J., Zhang, C., Yin, H., Zou, B., Geng, Y., Gao, W., Zhang, Y., Wang, G., Zheng, J., & Fang, L. (2025). TRIM56 enhances adenoviral E1A steady state to improve oncolytic adenovirus therapy efficacy. Journal of Virology. https://doi.org/10.1128/jvi.00041-25

Vancouver

Sun N, Zhang J, Zhang C, Yin H, Zou B, Geng Y, et al. TRIM56 enhances adenoviral E1A steady state to improve oncolytic adenovirus therapy efficacy. Journal of Virology. 2025. doi:10.1128/jvi.00041-25

BibTeX
@article{Sun2025,
  author = {Sun, Nan and Zhang, Jikai and Zhang, Chen and Yin, Hang and Zou, Botao and Geng, Yunfeng and Gao, Wanjun and Zhang, Yuxin and Wang, Gang and Zheng, Junnian and Fang, Lin},
  title = {TRIM56 enhances adenoviral E1A steady state to improve oncolytic adenovirus therapy efficacy},
  journal = {Journal of Virology},
  year = {2025},
  doi = {10.1128/jvi.00041-25}
}
Kostenlos starten →